Melissa Vilardebo
General Practice · Riverview, FLNPI 1700951985
Payments from drug & device makers
Across 1,353 payments — averaging $63.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$58K
- Otsuka America Pharmaceutical, Inc.$8K
- AbbVie$3K
- Tris Pharma Inc$1K
- Vanda Pharmaceuticals Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- plus $13K from 38 others
What the payments were for
- Consulting fees$3,5004%
- Speaking & faculty fees$42,85950%
- Travel & lodging$8,97510%
- Food & beverage$30,12135%
- Education$870%
- Gifts$20%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$52,006
- REXULTI$4,900
- NEUROSTAR TMS THERAPY$4,302
- ABILIFY MAINTENA$1,073
- VRAYLAR$613
- Equetro$421
- ZolpiMist$181
- Auvelity$126
- INVEGA SUSTENNA$121
- INVEGA TRINZA$121
- CAPLYTA$119
- SPRAVATO$110
How this compares
$85,543 in reported general payments places this provider in the 95th percentile of 6,901 general practice providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyvanseLisdexamfetamine Dimesylate | 18 | $7,188 |
| Lisdexamfetamine Dimesylate | 26 | $5,198 |
| AzstarysSerdexmethylphen/Dexmethylphen | 12 | $4,508 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 32 | $701 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 25 | $667 |
| Clonazepam | 39 | $316 |
| Methylphenidate Hcl | 22 | $289 |
| Alprazolam | 29 | $72 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $930 | $7,18818 claims |
| Corium, LLCAzstarys | $894 | $4,50812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,901 general practice providers in Florida.
Other general practice in Riverview
- Jose CardonaMiami$71M
- Lawrence GalitzMiami Gardens$42.5M
- Armando AcevedoMiami$15.2M
- Jorge AmayaMiami$14.2M
- Frank AlvarezHialeah$13.6M
- Hector RodriguezMiami$12.8M
- Eddie ArmasSouth Miami$12.4M
- Idalia AcostaMiami$11.4M
- Lilia Rodriguez AblesMiami$10.7M
- Jorge Monroy AvellaOcoee$10.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.